Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV
Ovarian Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer focused on measuring Epithelial ovary cancer F.I.G.O. stages III or IV, 70 years or older
Eligibility Criteria
Inclusion Criteria: Histological or cytological proven diagnosis of epithelial ovary cancer F.I.G.O stages III or IV (when only cytological proven diagnosis is available: malignant cells and pelvis tumoral mass and increased CA-125 must be diagnosed simultaneously) Patient aged > 70 years Neutrophil polynuclears > 1500/mm3 and Platelets > 100 000/mm3 No clinical icterus Life expectancy of at least 3 months Exclusion Criteria: Previous diagnosis of malignancy Previous chemotherapy treatment Previous radiotherapy Hypersensitivity to products containing Cremophore EL Hepatic values: bilirubine > 2*LSN, SGOT-SGPT > 2*LSN and/or Alkalin phosphatase > 3*LSN Myocardiopathy with arrhythmia
Sites / Locations
- Centre Hosptalier Emile Roux
- Centre Hospitalier Lyon-sud